SciClone to Present at Oppenheimer 23rd Annual Healthcare

SciClone to Present at Oppenheimer 23rd Annual Healthcare Conference
on December 13th 
FOSTER CITY, CA -- (Marketwire) -- 12/05/12 --   SciClone
Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm
Blobel, Chief Executive Officer, will present a corporate overview
and business update at the Oppenheimer 23rd Annual Healthcare
Conference on December 13, 2012 at 11:10 am ET at the Waldorf-Astoria
Hotel in New York City. 
To access the live audio webcast of these presentations, please log
on through a link located in the Investor Relations section of
SciClone's website at www.sciclone.com, under the Calendar of Events
tab. A replay of the webcasts will be available one hour after the
conclusion of the live events. 
About SciClone  
SciClone Pharmaceuticals is a US-based, China-focused specialty
pharmaceutical company with a product portfolio of therapies for
oncology, infectious diseases and cardiovascular, urological,
respiratory, and central nervous system disorders. SciClone's
ZADAXIN(R) (thymalfasin) is approved in over 30 countries and may be
used for the treatment of hepatitis B (HBV), hepatitis C (HCV) and
certain cancers, and as a vaccine adjuvant, according to the local
regulatory approvals. Besides ZADAXIN, SciClone markets about 14
mostly partnered pro
ducts in China, including Depakine(R), the most
widely prescribed broad-spectrum anti-convulsant in China;
Tritace(R), an ACE inhibitor for the treatment of hypertension;
Stilnox(R), a fast-acting hypnotic for the short-term treatment of
insomnia (marketed as Ambien(R) in the US); and Aggrastat(R), a
recently-launched interventional cardiology product. SciClone is also
pursuing the registration of several other therapeutic products in
China. SciClone is headquartered in Foster City, California. For
additional information, please visit www.sciclone.com.  
Ambien, Depakine, Stilnox and Tritace are registered trademarks of
Sanofi and/or its affiliates. 
Aggrastat is a registered trademark of Medicure International Inc. in
the United States, and Iroko Cardio LLC in numerous other countries. 
SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals
design, the SciClone logo and ZADAXIN are registered trademarks of
SciClone Pharmaceuticals, Inc. in the United States and numerous
other countries. 
Corporate Contacts 
Gary Titus
Chief Financial Officer
650.358.3456
gtitus@sciclone.com 
Jane Green 
Investors/Media
650.358.1447
jgreen@sciclone.com 
 
 
Press spacebar to pause and continue. Press esc to stop.